Industry snapshot
Key public data points
Historical & forecast
Base year 2023. Each series is official through its own latest government-data year (shown in the legend on each chart), and years beyond that are Claight estimates. As of July 2026 the current year is still in progress (2026 annual data is not yet published), so the forecast runs to 2028.
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Industry Definition and Scope
What does the Biotechnology in European Union industry cover?
The European Union biotechnology industry comprises enterprises engaged in applying biological science, cellular techniques, and genetic technologies to create commercial applications across health, industry, and agriculture. The industry is categorized into three major sub-sectors: red biotechnology (healthcare and pharmaceuticals), white biotechnology (industrial biomanufacturing and enzymes), and green biotechnology (agricultural and food processing). Activities range from foundational gene-editing research to large-scale biomanufacturing and commercialization.
- •Healthcare biotechnology dominates sector value, accounting for €32.75 billion of direct GVA in 2022 (EuropaBio / WifOR Study 2025).
- •Industrial biotechnology represents the fastest-growing sub-sector with €5.18 billion in GVA in 2022 (EuropaBio / WifOR Study 2025).
- •Agricultural biotechnology contributed €180 million in direct GVA in 2022 across the EU (EuropaBio / WifOR Study 2025).
Market Structure and Operators
Who operates in the industry and how is it structured?
The market structure is characterized by regional innovation clusters alongside high productivity per employee compared to traditional sectors. The ecosystem links early-stage research spin-offs and specialized small and medium-sized enterprises with large multinational pharmaceutical and industrial conglomerates. High capital expenditure requirements for clinical trials and specialized bioprocessing infrastructure concentrate commercial scaling within major Western and Northern European technology hubs.
- •Direct employment reached 238,170 jobs in 2022, with healthcare biotech accounting for 77.4% of direct employment (EuropaBio / WifOR Study 2025).
- •Average labor productivity reached €160,000 GVA per employee in 2022, nearly 2.8 times the EU economy average (EuropaBio / WifOR Study 2025).
- •Major biotech clusters remain geographically clustered in Germany, France, Belgium, Denmark, and the Netherlands (European Parliament Briefing 2026).
Demand Drivers
What drives demand in the industry?
Demand for EU biotechnology products is driven by healthcare needs associated with an aging population, rising global demand for complex biologics, and transition policies toward low-carbon biomanufacturing. Strategic initiatives aiming to secure medical autonomy within the EU also drive sustained public and private R&D funding into advanced therapies and diagnostic tools.
- •Total health sector corporate R&D investment across the EU reached €46 billion in 2024 (European Commission 2026 Briefing).
- •Biotechnology exports to non-EU nations reached €87.1 billion in 2022 (EuropaBio / WifOR Study 2025).
- •The sector achieved an extra-EU trade surplus of €51.7 billion in 2022, rising sevenfold relative to 2008 baseline levels (EuropaBio / WifOR Study 2025).
Competitive Landscape and Notable Public Companies
Who are the notable companies in the industry?
The competitive landscape consists of leading European life sciences corporations, specialized biopharmaceutical producers, and contract development and manufacturing organizations. European firms maintain competitive advantages in vaccine technologies, antibody therapies, and industrial enzymes, while competing against global biopharma peers from the United States and Asia.
- •BioNTech SE leads innovation in messenger RNA therapies and personalized oncology treatments.
- •Sanofi S.A. maintains large-scale biomanufacturing facilities and vaccine research programs across France and the EU.
- •Genmab A/S develops proprietary antibody technologies for oncology and immunology.
- •UCB S.A. operates heavily in biological drug development for severe neurological and immunological diseases.
Recent Trends and Outlook
What are the recent trends and outlook?
Recent trends reflect strong integration of artificial intelligence in early-stage candidate discovery, increased focus on biomanufacturing resilience, and targeted EU policy initiatives to bridge scale-up capital gaps. Policy emphasis focuses on retaining late-stage clinical trial activity and capital markets listing within Europe.
- •Direct corporate R&D contribution by biotech internal research reached €5.75 billion in 2022 (EuropaBio / WifOR Study 2025).
- •The European Commission's Strategy for European Life Sciences mobilizes over €10 billion annually from the EU budget (European Commission 2025).
- •Under Horizon Europe, €793 million was allocated in 2026-2027 specifically for Health Work Programme actions (European Commission 2025).
Regulation and Compliance
How is the industry regulated?
Biotechnology in the EU operates under stringent regulatory regimes managed by the European Medicines Agency for human healthcare products and the European Food Safety Authority for agricultural and industrial bio-inputs. Legislative frameworks focus on harmonizing clinical trials, streamlining regulatory pathways for advanced therapies, and creating regulatory sandboxes to accelerate time-to-market.
- •European Biotech Act I was proposed by the European Commission in December 2025 to streamline health biotech regulation and clinical trials.
- •Regulation (EU) No 536/2014 governs clinical trials across EU member states to harmonize approval procedures.
- •Regulation (EC) No 1394/2007 provides specific regulatory frameworks for Advanced Therapy Medicinal Products (ATMPs).
- •Regulation (EC) No 1829/2003 establishes approval standards for genetically modified food and feed products.
Sources
Government, statistical and trade sources used for this Claight analysis.
- EuropaBio / WifOR Institute Study 2025 ·
- European Commission Strategy for European Life Sciences 2025 ·
- European Parliament Briefing on European Biotech Act I 2026 ·
- Eurostat Science and Technology Database 2026
Claight analysis of public industry data.